Today we can announce that we have finalized the Sencell Clinical Development
Study (LFC-SEN-001) and it reveals accurate sensor performance in human
subjects. - This is a very important step in the right direction to develop the
next generation Continuous Glucose Monitor (CGM) for people with diabetes, says
CEO Joacim Holter. 

In this first clinical development study, the osmotic pressure based continuous
glucose sensor was clearly shown to track subcutaneous glucose concentrations at
least as good as the commercially available needle sensors.  

- The study output is as good as we had hoped for, and the production and
product development has been even better than expected throughout the study.
Both in an academic and strategic setup it is important for us to ensure that
our groundbreaking results are communicated clearly to the diabetes technology
community, and we have therefor decided to disclose our scientific results, says
Holter. The detailed results of this first-in human clinical study with Sencell
will be presented during the scientific program of the upcoming American
Diabetes Conference in San Diego on June 24th.  

- Beside successful results we are incredibly satisfied with how the
organization has overcome very challenging issues. Holter reminds that the
sensor company operates with complex and pioneering sensor technology, while
always having a focus on ensuring high quality at all stages of the process. -
The Lifecare team should be very proud of what they have achieved so far, says
Holter. 

The clinical performance characteristics of these wired prototypes provide us
with strengthened and valuable knowledge for the next steps of product
development. - We strongly believe that this forms a solid knowledge base when
we develop the sensor with integrated wireless data transmission, says Holter. 

In April Lifecare announced that a sensor first used in our Clinical Development
Study had confirmed an operational longevity of 12 weeks in a continued
laboratory (in vitro) set up.     - All this together is absolutely a
breakthrough, considering today's CGM technology. Hopefully this is a
significant step towards Lifecare's goal of contributing to helping people with
diabetes to live a normal life. 

______________________________________________________ 

Lifecare AS is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare's main focus is to
bring the next generation of Continuous Glucose Monitoring ("CGM") systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on
the sensor body for read-out of pressure variations. LifecareŽs sensor
technology is referred to as "Sencell" and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the human
body. 

______________________________________________________ 

Contact: Joacim Holter, CEO, tel. +47 40059050, epost: joacim.holter@lifecare.no


This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Joacim Holter, CEO at Lifecare AS, on 11 Mai 2023
at 10:40 CET